Loading clinical trials...
Loading clinical trials...
A Phase 2 Open-label Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER) Tablets in GNE Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy (HIBM)) Patients With Severe Ambulatory Impairment
Conditions
Interventions
Aceneuramic Acid Extended-Release
Locations
5
United States
University of California, Irvine
Orange, California, United States
Washington University, St. Louis
St Louis, Missouri, United States
NYU Langone Medical Center
New York, New York, United States
University Alexandrovska, Bulgaria
Sofia, Bulgaria
McMaster University
Hamilton, Ontario, Canada
Start Date
April 29, 2016
Primary Completion Date
January 10, 2018
Completion Date
January 10, 2018
Last Updated
February 19, 2019
NCT04671472
NCT00195637
NCT02377921
NCT01634750
NCT01517880
Lead Sponsor
Ultragenyx Pharmaceutical Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions